HPi1|cas:13080-21-2|西域试剂

HPi1,98.0%

产品编号：Bellancom-120536| CAS NO：13080-21-2| 分子式：C₈H₈N₄S| 分子量：192.24

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-120536	￥500.00	杭州北京（现货）
Bellancom-120536	￥800.00	杭州北京（现货）
Bellancom-120536	￥2400.00	杭州北京（现货）
Bellancom-120536	￥3400.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

HPi1

产品介绍

HPi1 是一种针对幽门螺杆菌 (Helicobacter pylori) 的有效，选择性和具有口服活性的抗菌剂，IC₅₀ 为 0.24 μM，MIC 为 0.08-0.16 μg/mL。HPi1 对其他细菌无活性，包括肠道菌干酪乳杆菌，罗伊氏乳杆菌和长双歧杆菌。

生物活性

HPi1 is a potent, selective and orally active antimicrobial against Helicobacter pylori with an IC₅₀ of 0.24 μM and an MIC of 0.08-0.16 μg/mL. HPi1 is inactive against other bacteria, including the gut commensals Lactobacillus casei, Lactobacillus reuteri, and Bifidobacterium longum.

体外研究

The MIC against H. pylori isolates ranged from 0.002-0.032 μg/mL (0.01-0.17 μM) in the agar dilution assay. HPi1 is effective against the clarithromycin-resistant strains ARHp172 (MIC of 0.004–0.016 μg/mL) and ARHp246 (MIC of 0.008–0.032 μg/mL).
HPi1 has some activity against the Bacteroides species, but at concentrations at least 18-fold higher than the H. pylori MIC. More potent activity is detected for Campylobacter jejuni with an MIC of 0.3 μg/mL.
HPi1 has good physicochemical and pharmacological properties, including determining the aqueous solubility (19 μg/mL), human plasma protein binding (93% bound), stability with human liver microsomes (T_1/2 of 1.3 hours) and the ability to passively permeate membranes.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

HPi1 (6.25-50 mg/kg; Oral gavage; once a day; for 3 days; female C57BL/6 mice) treatment decreases colony counts below the limit of detection at doses of 25 or 50 mg/kg/day.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Adult specific-pathogen-free female C57BL/6 mice (6-8-week-old) fed with H. pylori SS1 suspension
Dosage:	6.25 mg/kg, 12.5 mg/kg, 25 mg/kg, 50 mg/kg
Administration:	Oral gavage; once a day; for 3 days
Result:	Reduced colony counts to below the limit of detection.

体内研究

HPi1 (6.25-50 mg/kg; Oral gavage; once a day; for 3 days; female C57BL/6 mice) treatment decreases colony counts below the limit of detection at doses of 25 or 50 mg/kg/day.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Adult specific-pathogen-free female C57BL/6 mice (6-8-week-old) fed with H. pylori SS1 suspension
Dosage:	6.25 mg/kg, 12.5 mg/kg, 25 mg/kg, 50 mg/kg
Administration:	Oral gavage; once a day; for 3 days
Result:	Reduced colony counts to below the limit of detection.

性状

Solid

溶解性数据

In Vitro:

DMSO : 62.5 mg/mL (325.11 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	5.2018 mL	26.0092 mL	52.0183 mL
5 mM	1.0404 mL	5.2018 mL	10.4037 mL
10 mM	0.5202 mL	2.6009 mL	5.2018 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (10.82 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (10.82 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明